AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. More Details
Excellent balance sheet and fair value.
Share Price & News
How has AVROBIO's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVRO has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AVRO underperformed the US Biotechs industry which returned 39.3% over the past year.
Return vs Market: AVRO underperformed the US Market which returned 19.5% over the past year.
Price Volatility Vs. Market
How volatile is AVROBIO's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAVROBIO (NASDAQ:AVRO) Is In A Good Position To Deliver On Growth Plans
5 months ago | Simply Wall StWe're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Rate
8 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The AVROBIO, Inc.'s (NASDAQ:AVRO) Shareholder Register?
Is AVROBIO undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVRO ($16.14) is trading below our estimate of fair value ($68.78)
Significantly Below Fair Value: AVRO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AVRO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AVRO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVRO is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.6x).
How is AVROBIO forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVRO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVRO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVRO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if AVRO's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if AVRO's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVRO is forecast to be unprofitable in 3 years.
How has AVROBIO performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVRO is currently unprofitable.
Growing Profit Margin: AVRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVRO is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.
Accelerating Growth: Unable to compare AVRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: AVRO has a negative Return on Equity (-39.46%), as it is currently unprofitable.
How is AVROBIO's financial position?
Financial Position Analysis
Short Term Liabilities: AVRO's short term assets ($251.0M) exceed its short term liabilities ($15.4M).
Long Term Liabilities: AVRO's short term assets ($251.0M) exceed its long term liabilities ($370.0K).
Debt to Equity History and Analysis
Debt Level: AVRO is debt free.
Reducing Debt: AVRO has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVRO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if AVRO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is AVROBIO current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Geoff MacKay (54 yo)
Mr. Geoff MacKay, BSc, serves as Chief Executive Officer and President of AVROBIO Inc. Mr. MacKay served as Interim Chief Executive Officer at Egenesis Inc. Mr. MacKay is an Atlas Advisor at Atlas Venture ...
CEO Compensation Analysis
Compensation vs Market: Geoff's total compensation ($USD1.82M) is about average for companies of similar size in the US market ($USD1.91M).
Compensation vs Earnings: Geoff's compensation has been consistent with company performance over the past year.
|Co- Founder||4.92yrs||US$1.82m||1.35% |
|CFO & Treasurer||1.75yrs||US$2.75m||0.0020% |
|Chief Legal Officer & Secretary||1.75yrs||US$1.38m||0% |
|Scientific Founder||no data||no data||no data|
|Head of Operations||0.75yr||no data||no data|
|Chief Manufacturing & Technology Officer||0.33yr||no data||no data|
|Chief Scientific Officer||no data||no data||no data|
|Senior Vice President of Corporate Communications||0.75yr||no data||no data|
|Chief Human Resources Officer||1.17yrs||no data||no data|
|Chief Business Officer||no data||no data||0.42% |
|Senior Vice President of Portfolio & Program Management||3.92yrs||no data||no data|
|Chief Commercial Officer||1yr||no data||no data|
Experienced Management: AVRO's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
|Co- Founder||4.92yrs||US$1.82m||1.35% |
|Independent Director||2.75yrs||US$142.55k||0% |
|Independent Non-Employee Director||2.33yrs||US$145.05k||0% |
|Independent Chairman of the Board||4.67yrs||US$168.80k||no data|
|Independent Director||1.75yrs||US$344.87k||0% |
|Independent Director||2.5yrs||US$144.55k||0% |
|Independent Director||4.75yrs||US$145.30k||0.69% |
Experienced Board: AVRO's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.
AVROBIO, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AVROBIO, Inc.
- Ticker: AVRO
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$587.997m
- Shares outstanding: 36.43m
- Website: https://www.avrobio.com
Number of Employees
- AVROBIO, Inc.
- Building 300
- Suite 201
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AVRO||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2018|
AVROBIO, Inc., a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies e ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 01:11|
|End of Day Share Price||2020/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.